| Project/Area Number |
25871159
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Hematology
Tumor biology
|
|---|
| Research Institution | National Cancer Center Japan |
|---|
Principal Investigator |
OGAWARA Yoko 独立行政法人国立がん研究センター, 研究所, 研究員 (30599626)
|
|---|
| Project Period (FY) |
2013-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2014: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2013: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | NPM / IDH / AML / 2HG / 5hmC / 低酸素 / YB-1 |
|---|
| Outline of Final Research Achievements |
In normal karyotype acute myeloid leukemia (AML), simultaneous mutations in NPM, IDH, DNMT3A and FLT3 occur frequently. We generated AML mouse model, the onset of which depends on these four mutant genes. By using these AML model mice, we showed that IDH mutant inhibits differentiation of cells and is necessary for the maintenance of leukemia stem cells. This study is the first to demonstrate that IDH mutant is a reasonable therapeutic target for cancer.
|
